Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

prnewswire.com
XOMA The article reports on an investigation into the proposed acquisition of XOMA Royalty Corporation by Ligand Pharmaceuticals. While the acquisition details are provided, the investigation suggests potential concerns for XOMA shareholders, leading to a neutral sentiment as the outcome is uncertain. LGND Ligand Pharmaceuticals is proposing to acquire XOMA Royalty Corporation. The article focuses on the investigation into the acquisition's terms, not on Ligand's performance or future prospects, thus resulting in a neutral sentiment for LGND.

NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold. The transaction is valued at approximately $739 million and is expected to close in the third quarter of 2026.

If you are a stockholder of XOMA Royalty Corporation and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/xoma/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).

Rowley Law PLLC represents stockholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.

Attorney Advertising. Prior results do not guarantee a similar outcome.

SOURCE Rowley Law PLLC